Lantheus Holdings, Inc. $LNTH Shares Purchased by Comerica Bank

Key Points

• Comerica Bank increased its stake in Lantheus Holdings by 14.7% during the first quarter, owning approximately 0.44% of the company, valued at $29.7 million.
• Lantheus reported earnings of $1.57 per share for the last quarter, missing analysts' expectations, with revenues down 4.1% year-over-year.
• Insiders sold a total of 6.8 million shares of Lantheus stock worth over $384 million in the past 90 days, significantly decreasing their ownership stakes.

Comerica Bank raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 14.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 304,160 shares of the medical equipment provider's stock after buying an additional 38,974 shares during the quarter. Comerica Bank owned about 0.44% of Lantheus worth $29,686,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of LNTH. Janus Henderson Group PLC boosted its stake in Lantheus by 72.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC raised its position in Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the period. TD Asset Management Inc lifted its stake in Lantheus by 1,028.0% during the first quarter. TD Asset Management Inc now owns 682,614 shares of the medical equipment provider's stock worth $66,623,000 after purchasing an additional 622,100 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Lantheus in the 1st quarter valued at $55,941,000. Finally, Assenagon Asset Management S.A. grew its position in Lantheus by 1,196.4% in the 1st quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock valued at $32,817,000 after acquiring an additional 310,301 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

Shares of LNTH opened at $58.21 on Monday. The stock has a 50-day simple moving average of $71.48 and a 200-day simple moving average of $84.19. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The stock has a market capitalization of $3.96 billion, a PE ratio of 15.48 and a beta of 0.14. Lantheus Holdings, Inc. has a 1 year low of $47.25 and a 1 year high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.08). The business had revenue of $378.05 million for the quarter, compared to analyst estimates of $389.69 million. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.Lantheus's revenue was down 4.1% on a year-over-year basis. During the same period last year, the business posted $1.80 EPS. On average, analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Mary Anne Heino sold 26,066 shares of the business's stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the completion of the sale, the director owned 318,650 shares in the company, valued at $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 6,838,066 shares of company stock worth $384,430,031 over the last 90 days. 1.50% of the stock is owned by insiders.

Analyst Ratings Changes

LNTH has been the subject of several recent research reports. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Thursday, May 8th. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research report on Wednesday, July 16th. JMP Securities cut their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research report on Thursday, August 7th. B. Riley decreased their price objective on Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a research note on Monday, June 23rd. Finally, Truist Financial set a $63.00 price objective on Lantheus and gave the company a "hold" rating in a research note on Monday, August 11th. Five analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Lantheus presently has an average rating of "Moderate Buy" and a consensus price target of $105.50.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

Want to see what other hedge funds are holding LNTH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.